On June 3, 2024, Mangoceuticals, Inc. experienced a significant event involving its stock ownership. Jacob D. Cohen, the company's CEO and Chairman, received an issuance of 800,000 fully-vested shares of common stock as a bonus for the year 2024. This decision was approved by the Board of Directors with the recommendation of the Compensation Committee. The Schedule 13D/A filing with the SEC, which is an amendment to the previous filings, reflects this change. As a result, Jacob D. Cohen now beneficially owns 10,575,000 shares, representing 34.7% of the company's common stock. Additionally, The Tiger Cub Trust, also a reporting person, holds 8,275,000 shares, which accounts for 28.6% of the common stock. These ownership percentages are based on 28,943,143 shares of common stock outstanding as of June 5, 2024. The filing confirms that no other person has the right to receive dividends or proceeds from the sale of the securities owned by the reporting persons.

On June 3, 2024, Mangoceuticals, Inc. experienced a significant event involving its stock ownership. Jacob D. Cohen, the company's CEO and Chairman, received an issuance of 800,000 fully-vested shares of common stock as a bonus for the year 2024. This decision was approved by the Board of Directors with the recommendation of the Compensation Committee. The Schedule 13D/A filing with the SEC, which is an amendment to the previous filings, reflects this change. As a result, Jacob D. Cohen now beneficially owns 10,575,000 shares, representing 34.7% of the company's common stock. Additionally, The Tiger Cub Trust, also a reporting person, holds 8,275,000 shares, which accounts for 28.6% of the common stock. These ownership percentages are based on 28,943,143 shares of common stock outstanding as of June 5, 2024. The filing confirms that no other person has the right to receive dividends or proceeds from the sale of the securities owned by the reporting persons.